Clearmind Medicine (CMND) recently announced that it signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health ...

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol ...

Shares of Clearmind Medicine more than doubled after the Institutional Review Board approved a clinical trial of its flagship compound as a treatment for alcohol use disorder. The stock was changing ...

The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the ...

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind ...

Clearmind Medicine Inc. has signed a non-binding term sheet with Dr. Glitter Pty Ltd to collaborate on the development and commercialization of a MEAI-based alcohol substitute using Dr. Glitter's ...

Clearmind Medicine (CMND) has signed a non-binding term sheet with Dr. Glitter. The two companies plan to collaborate on the development and commercialization of Clearmind’s proprietary MEAI ...

The term sheet is non-binding, subject to the execution of a definitive agreement Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” ...

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format Vancouver, Canada, Dec.

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the ...